Dulaglutide: the long-awaited new agent to treat type 2 diabetes
78 minutes to Watch
Contributor
Dr Ryan Paul (Ngāti Maru)
2 September 2021
Hover over the timeline to find the different chapters in this video.

Dr Paul is an academic endocrinologist at Waikato District Health Board and at the University of Waikato. He is an executive member of the New Zealand Society for the Study of Diabetes (NZSSD) and recently led the development of the NZSSD guidance on the management of type 2 diabetes in New Zealand. Dr Paul is heavily involved in teaching primary care clinicians, diabetes nurse prescribers and endocrinology trainees.

This resource will not be available after 30 June 2024 as He Ako Hiringa is shutting down. If your organisation would like to host this resource please contact admin@akohiringa.co.nz

Webinar outline

Presented by diabetologist Dr Ryan Paul, this recorded webinar explores:

  • When and how to use dulaglutide for type 2 diabetes
  • Advice on whether to choose funded dulaglutide or empagliflozin and when to switch between the two
  • When to advise to self-fund dulaglutide
  • The potential for dulaglutide to get patients off insulin
  • The role of dulaglutide in primary and secondary prevention of CVD.

You can find the slides from this webinar here.

More information on dulaglutide is available at:

This webinar was recorded from a live Zoom presentation hosted by Mobile Health on 25 August 2021. This video has been edited for clarity.

Timeline

  • 00:00 - 00:53 Introduction
  • 00:53 - 51:50 Dr Ryan Paul
  • 51:50 - 1:18:11 Q&A and closing

Professional college endorsements

This activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1.25 CME credits for continuing professional development purposes (1 credit per learning hour). To claim your CPD credits, log in to your Te Whanake dashboard and record these activities under the appropriate learning category.

endorsed

We'd love your feedback

Related Articles